medigraphic.com
Academia Mexicana de Neurología, A.C.

2005, Number 5

<< Back

Rev Mex Neuroci 2005; 6 (5)

Guillain-Barré syndrome and related disorders

Amato AA

Language: English
References: 43
Page: 455-469
PDF size: 112.99 Kb.


ABSTRACT

In 1859, Landry described a neuropathy characterized by acute ascending paralysis. Subsequently, Guillain, Barré, and Strohl noted the areflexia and the albuminocytological dissociation in the cerebral spinal fluid (CSF) associated with this neuropathy. The contributions of Landry and Strohl have been neglected and the neuropathy has been most commonly referred to as Guillain-Barré syndrome (GBS). In 1949, Haymaker and Kernohan reported the histopathological features of 50 fatal cases of GBS.


REFERENCES

  1. Modified with permission from: Amato AA, Dumitru D. Acquired Neuropathies. In: Dumitru D, Amato AA, Swartz MJ (Eds.). Electrodiagnostic Medicine. 2nd Ed. Philadelphia: Hanley & Belfus, Inc.; 2002, p. 937-1041.

  2. Bril V, Ilse WK, Pearse R, et al. Pilot trial of immunoglobulin versus plasma exchange in patients with Guillain-Barré syndrome. Neurology 1996; 46: 100-3.

  3. Castro LHM, Ropper AH. Human immune globulin infusion in Guillain-Barré syndrome: worsening during and after treatment. Neurology 1993; 43: 1034-6.

  4. Cornblath DR, Mellits ED, Griffin JW, et al. Motor conduction studies in Guillain-Barré syndrome: Description and prognostic value. Ann Neurol 1988; 23: 354-9.

  5. Cornblath DR. Electrophysiology in Guillain-Barré syndrome. Ann Neurol 1990; 27(Suppl): S17-S20.

  6. Dalakas MC. Autoimmune ataxic neuropathies (sensory ganglinopathies): are glycolipids the responsible autoantigens? Ann Neurol 1996; 39: 419-42.

  7. Dutch Guillain-Barré Study Group. Treatment of Guillain-Barré syndrome with high-dose immune globulins combined with methylprednisolone: a pilot study. Ann Neurol 1994; 35: 749-52.

  8. Feasby TE, Gilbert JJ, Brown WF, et al. An acute axonal form of Guillain-Barré polyneuropathy. Brain 1986; 109: 1115-26.

  9. Feasby TE, Hahn A, Brown W, Bolton CF, Gilbert JJ, Koopman WJ. Severe axonal degeneration in acute Guillain-Barré syndrome: evidence of two different mechanism? J Neurol Sci 1993; 116: 185-92.

  10. Feasby TE, Hughes RAC. Campylobacter jejuni, antigangliosides antibodies, and Guillain-Barré syndrome. Neurology 1998; 51: 340-2.

  11. French Cooperative Group on Plasma Exchange in Guillain-Barré syndrome. Efficiency of plasma exchange in Guillain-Barré syndrome: Role of replacement fluids. Ann Neurol 1987; 22: 753-61.

  12. French Cooperative Group on Plasma Exchange in Guillain-Barré syndrome. The appropriate number of plasma exchanges in Guillain-Barré syndrome. Ann Neurol 1997; 41: 298-306.

  13. Griffin JW, Li CY, Ho TW, et al. Guillain-Barré syndrome in northern China: The spectrum of neuropathologic changes in clinically defined cases. Brain 1995; 118: 577-95.

  14. Griffin JW, Li CY, Ho TW, et al. Pathology of the motor-sensory axonal Guillain-Barré syndrome. Ann Neurol 1996; 39: 17-28.

  15. Guillain-Barré Study Group. Plasmapheresis and acute Guillain-Barré syndrome. Neurology 1985; 35: 1096-104.

  16. Guillain-Barré Syndrome Steroid Trial Group. Double-blind trial of intravenous methylprednisolone in Guillain-Barré syndrome. Lancet 1993; 341: 586-90.

  17. Guillain G, Barré JA, Strohl A. Sur un syndrome de radiculo-nevrite avec hyper albiminose du loquide cephalo-rachiden sas reaction cellulaire. Remarques sur les caracteres cliniques et graphiques des reflexes tendeneux. Bulletins et memories de la societe medicale des hospitaux de Paris. Masson et Cie 1916; 40: 1462-70.

  18. Hafer-Macko C, Hsieh ST, Li CY, et al. Acute motor axonal neuropathy: an antibody mediated attack on axolemma. Ann Neurol 1996; 40: 635-44.

  19. Hafer-Macko C, Sheihk KA, Li CY, et al. Immune attack on the Schwann cell surface in acute inflammatory demyelinating polyneuropathy. Ann Neurol 1996; 39: 625-35.

  20. Hartung HP, Pollard JD, Harvey GK, Toyka KV. Immunopathogenesis and treatment of the Guillain-Barré syndrome. Part I. Muscle Nerve 1995; 18: 137-53.

  21. Hartung HP, Pollard JD, Harvey GK, Toyka KV. Immunopathogenesis and treatment of the Guillain-Barré syndrome. Part II. Muscle Nerve 1995; 18: 154-64.

  22. Ho TW, Mishu B, Li CY, et al. Guillain-Barré syndrome in northern China: Relationship to Campylobacter jejuni infection and antiglycolipid antibodies. Brain 1995; 118: 597-605.

  23. Irani DN, Cornblath DR, Chaudry V, Borel C, Hanley DF. Relapse in Guillain-Barré syndrome after treatment with human immune globulin. Neurology 1993; 43: 1034-6.

  24. Jackson CE, Barohn RJ, Mendell JR. Acute paralytic syndrome in three American men. Arch Neurol 1993; 50: 732-5.

  25. Low PA, Dyck PJ, Lambert EH, et al. Acute pandysautonomic neuropathy. Ann Neurol 1983; 13: 412-17.

  26. McKhann GM, Griffin JW, Cornblath DR, et al. Plasmapheresis and Guillain-Barré syndrome: analysis of prognostic factors and the effect of plasmapheresis. Ann Neurol 1988; 23: 347-53.

  27. McKhann GM, Cornblath DR, Ho TW, et al. Clinical and electrophysiological aspects of acute paralytic disease of children and young adults in northern China. Lancet 1991; 338: 593-7.

  28. McKhann GM, Cornblath DR, Griffin JW, et al. Acute motor axonal neuropathy in northern China: The spectrum of neuropathologic changes in clinically defined cases. Brain 1995; 118: 577-95.

  29. Mericle RA, Triggs WJ. Treatment of acute pandysautonomia with intravenous immunoglobulin. J Neurol Neurosurg Psychiatry 1997; 62: 529-31.

  30. Meulstee J, van der Meche’, the Dutch Guillain-Barré Study Group. J Neurol Neurosurg Psychiatry 1995; 59: 482-6.

  31. Miller RG, Peterson GW, Daube JR, et al. Prognostic value of electrodiagnosis in Guillain-Barré syndrome. Muscle Nerve 1988; 11: 769-74.

  32. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Randomized trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome. Lancet 1997; 349: 225-30.

  33. Smith AA, Vermeulen M, Koelman J, Wielman J, Wieling W. Unusual recovery from acute pandysautonomia after immunoglobulin therapy. Mayo Clin Proc 1997; 72: 333-5.

  34. van der Meche’ FGA, Schmidtz PIM, the Dutch Guillain- Barré Study Group. A randomized trial comparing intravenous immunoglobulin and plasma exchange in Guillain-Barré syndrome. N Engl J Med 1992; 326: 1123-9.

  35. van Koningsveld R, Schmitz PI, Meche FG, Visser LH, Meulstee J, van Doorn PA. Dutch GBS study group. Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barre syndrome: randomised trial. Lancet 2004; 363(9404): 192-6.

  36. Van den Bergh PY, Pieret F. Electrodiagnostic criteria for acute and chronic inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve 2004; 29(4): 565-74.

  37. Hung PL, Chang WN, Huang LT, Huang SC, Chang YC, Chang CJ, Chang CS, Wang KW, Cheng BC, Chang HW, Lu CH. A clinical and electrophysiologic survey of childhood Guillain-Barre syndrome. Pediatric Neurology 2004; 30(2): 86-91.

  38. Hughes RA, Wijdicks EF, Barohn R, Benson E, Cornblath DR, Hahn AF, Meythaler JM, Miller RG, Sladky JT, Stevens JC. Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter: immunotherapy for Guillain-Barre syndrome: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2003; 61(6): 736-40.

  39. Pritchard J, Gray IA, Idrissova ZR, Lecky BR, Sutton IJ, Swan AV, Willison HJ, Winer JB, Hughes RA. A randomized controlled trial of recombinant interferon-beta 1a in Guillain-Barre syndrome. Neurology 2003; 61(9): 1282-4.

  40. Tekgul H, Serdaroglu G, Tutuncuoglu S. Outcome of axonal and demyelinating forms of Guillain-Barre syndrome in children. Ped Neurol 2003; 28(4): 295-9.

  41. Jacobs BC, O’Hanlon GM, Bullens RW, Veitch J, Plomp JJ, Willison HJ. Immunoglobulins inhibit pathophysiological effects of anti-GQ1b-positive sera at motor nerve terminals through inhibition of antibody binding. Brain 2003; 126: 2220-34.

  42. Kwa MS, van Schaik IN, De Jonge RR, Brand A, Kalaydjieva L, van Belzen N, Vermeulen M, Baas F. Autoimmunoreactivity to Schwann cells in patients with inflammatory neuropathies. Brain 2003; 126: 361-75.

  43. Seneviratne U, Gunasekera S. Acute small fiber sensory neuropathy: another variant of Guillain-Barre syndrome? J Neurol Neurosurg Psychiatry 202; 72: 540-2.




2020     |     www.medigraphic.com